Search clinical trials for: SC Peginterferon beta-1a

Total 204 results

Synairgen Research Ltd.

Completed

Comparing Efficacy and Safety of Inhaled SNG001 to Placebo

Asthma

United Kingdom
Biogen

Completed

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy (SAFE)

Multiple Sclerosis

Sweden
Synairgen Research Ltd.

Completed

A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Biogen

Completed

A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers

Healthy

United States
Merck KGaA, Darmstadt, Germany

Completed

An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone (RETURN)

Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone (REMAIN)

Multiple Sclerosis, Relapsing-Remitting
PD Dr. Marcus Müller
BfARM, Bonn; DZNE, Bonn

Unknown

Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RESI)

Relapsing-remitting Multiple Sclerosis

Germany
Biogen

Completed

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Active Ulcerative Colitis

United States, Canada, Czech Republic, Hungary, Poland, Russian Federation, Slovakia
University Health Network, Toronto
Michael Garron Hospital

Completed

Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19 (ILIAD)

Covid-19 | Sars-CoV2

Canada, Brazil
University Health Network, Toronto

Active, not recruiting

TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19

Covid19 | Sars-CoV2

Canada
Icahn School of Medicine at Mount Sinai
Eiger BioPharmaceuticals

Withdrawn

Interferon Lambda Therapy for COVID-19

SARS-CoV-2
Biogen

Completed

Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen (SFERA)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Clinical Isolated Syndrome (CIS)

Czech Republic, Switzerland
EMD Serono
Pfizer

Completed

Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis (RNF)

Multiple Sclerosis

United States
Biogen

Completed

Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)

Multiple Sclerosis | Pregnancy | Prenatal Exposure Delayed Effects

United States
EMD Serono
Pfizer

Completed

RNF and Betaseron® Tolerability Study (REFORMS)

Relapsing Remitting Multiple Sclerosis (RRMS)

United States
AstraZeneca

Completed

A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection (INEXAS)

Asthma

France, United Kingdom, Korea, Republic of, Argentina, Australia, Spain, Colombia
EMD Serono

Terminated

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate (RESOunD)

Multiple Sclerosis

United States
Trio Medicines Ltd.
Biogen

Completed

Avonex®: Safety, Blood Levels and Effects (C-851)

Multiple Sclerosis (MS)

United Kingdom
Merck KGaA, Darmstadt, Germany
Merck Serono Middle East FZ LLC

Completed

Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

Relapsing Multiple Sclerosis (RMS)

Bulgaria, Poland, Argentina, Hungary, Korea, Republic of, Saudi Arabia, Egypt, Algeria, Bahrain, Iran, Islamic Republic of, Kuwait, Lebanon, Morocco
Beth Israel Deaconess Medical Center
Biogen

Completed

Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis (CHAMPIONS10)

Multiple Sclerosis | Optic Neuritis | Transverse Myelitis | Acute Brainstem/Cerebellar Syndrome

United States, Canada
Biogen
AbbVie

Completed

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis ((DECIDE))

Relapsing-Remitting Multiple Sclerosis

Sweden, United States, Brazil, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Ukraine, Denmark, Finland, Romania, Canada, France, Hungary, Israel, Switzerland, Serbia, India, Mexico, Poland, Georgia, Ireland, Argentin... and more
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Spain, Czechia, Belgium, Italy, Canada, United Kingdom, Germany, Ireland, Turkey, Poland, Russian Federation, Ukraine, Croatia, Argentina, France, Belarus, Brazil, Mexico, Bosnia and Herzegovina, Bulgaria, Slovakia, S... and more
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C (BASIS)

Hepatitis C Virus (HCV)

Mexico, Korea, Republic of, Czech Republic
Bristol-Myers Squibb

Completed

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy (STRUCTURE)

Hepatitis C

France, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Taiwan, United Kingdom, United States, Spain, Israel, Argentina, Poland
Merck KGaA, Darmstadt, Germany

Completed

Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis

Multiple Sclerosis

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Belgium, Czechia, Russian Federation, Serbia, Spain, Italy, Netherlands, Finland, Estonia, Brazil, France, Germany, Poland, Switzerland, Ukraine, Peru, Argentina, Lithuania, Slovakia, Portugal, Australia, Hungary, Tunisia, Bulgar... and more
Biogen

Completed

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY)

Multiple Sclerosis

United States, Spain, Hungary, Serbia, Canada, France, Poland, Russian Federation, Netherlands, Czech Republic, Italy, United Kingdom
Faron Pharmaceuticals Ltd

Terminated

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA (INFORAAA)

Preventive Medicine | Multi Organ Failure

Lithuania, Estonia, Finland
Nancy Hammond, MD
Kansas City Area Life Sciences Institute, Inc.

Completed

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

Multiple Sclerosis | Low Bone Density

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®) (BRAVO)

Multiple Sclerosis

United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Israel, Italy, Lithuania, North Macedonia, Poland, Puerto Rico, Romania, Russian Federation, Slovakia, South Africa, Spain, Ukraine
Celgene

Completed

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) (SUNBEAM)

Multiple Sclerosis

United States, Spain, Czechia, Russian Federation, Portugal, Serbia, United Kingdom, New Zealand, Belarus, Bulgaria, Poland, Romania, Estonia, Germany, Sweden, Ukraine, Hungary, Croatia, Georgia, Bosnia and Herzegovina, Latvia, Li... and more
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Completed

Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a (CONTAIN)

Multiple Sclerosis

Italy
Bosnalijek D.D
MonitorCRO

Recruiting

A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS

Multiple Sclerosis, Relapsing-Remitting

Turkey
Fundación de Investigación Biomédica - Hospital...
Haematology Service,

Unknown

Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)

Multiple Mieloma

Spain
Louisiana State University Health Sciences Center...
Biogen

Completed

Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis

Multiple Sclerosis

United States
Merck KGaA, Darmstadt, Germany
Merck B.V., Netherlands; Merck A.E., Greece; Merck OY, Finland; Merck A.B., Sweden and other collaborators

Completed

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) (STAR)

Multiple Sclerosis, Relapsing Remitting

Greece
Biogen

Completed

Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

Multiple Sclerosis

United States
Teva Neuroscience, Inc.

Completed

Therapy Optimization in Multiple Sclerosis (MS) (TOP MS)

Multiple Sclerosis

United States
EMD Serono
Pfizer

Completed

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

United States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
Shahid Beheshti University of Medical Sciences

Unknown

the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19

Covid19
Biogen

Recruiting

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Multiple Sclerosis

United States, Germany
Biogen
Elan Pharmaceuticals

Terminated

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS)

Relapsing Remitting Multiple Sclerosis

United States, Czech Republic, Italy, Spain, Sweden, Latvia, Finland, Hungary, Poland, Slovenia, Australia, Canada, France
Biogen

Completed

Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis (SIMCOMBIN)

Multiple Sclerosis

Denmark
Biogen

Completed

Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? (FLAIR)

Relapsing Remitting Multiple Sclerosis

Belgium, Luxembourg, United Kingdom
Aaron Boster
Pfizer; EMD Serono

Completed

Combination Therapy Using Cellcept and Rebif in RRMS

Multiple Sclerosis

United States
Qassim University

Unknown

Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic

COVID-19
Dr. Conrado Fernandez

Completed

High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (DARGEN-3)

Chronic Hepatitis C

Spain
Biogen

Active, not recruiting

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CONNECT)

Relapsing-Remitting Multiple Sclerosis

Italy, Belgium, United States, Hungary, Sweden, United Kingdom, Israel, France, Czechia, Poland, Serbia, Denmark, Spain, Turkey, Bulgaria, Germany, Canada, Kuwait
EMD Serono

Terminated

Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease

Crohn's Disease

Germany, Italy, Sweden, Switzerland, United Kingdom
Azidus Brasil

Completed

Pharmacokinetics and Pharmacodynamics of the Interferon Beta-1a Produced by Laboratorio Quimico Farmaceutico Bergamo Compared to Interferon Beta-1a (Rebif - Merck Serono) in Healthy Subjects

Healthy

Brazil

Search clinical trials for: SC Peginterferon beta-1a

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations